Compare iShares Core S&P 500 ETF (IVV) vs Novo Nordisk A/S (NVO) Price & Performance

iShares Core S&P 500 ETFTrade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

iShares Core S&P 500 ETF vs Novo Nordisk A/S — how do they compare? iShares Core S&P 500 ETF trades at $776.4, while Novo Nordisk A/S trades at $46.43 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while iShares Core S&P 500 ETF pays none, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.

	IVV	NVO
Sector	Broad Market / Factor	Health
52-Week High	$776.81	$63.98
52-Week Low	$634.93	$35.29
Market Cap	—	$207.85B
Enterprise Value	—	$222.55B
Dividend Yield	—	3.81%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core S&P 500 ETF

IVV, tracking the S&P 500, trades at $776.18, down 0.07% with a bullish technical outlook from moving averages but overbought RSI signals. Recent news highlights record highs and institutional activity, with JPMorgan raising its S&P 500 target to 8,000 amid strong earnings growth. The ETF shows resilience despite valuation concerns.

Outlook remains positive due to AI-driven earnings growth, but risks include high valuations and market volatility. Investors benefit from broad market exposure, yet should monitor inflation reports and geopolitical events that could trigger pullbacks.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.

Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

IVV

WisdomTree U.S. Total Dividend ETF (DTD) rated 'hold' for balanced factors but overlaps 57% with S&P 500 ETFs.Seeking Alpha · 2 days agoNeutral Main Sector Rotation ETF (SECT) gets Hold rating due to weak performance versus IVV.Seeking Alpha · 4 days agoNeutral View details →

NVO

Novo Nordisk sues Eli Lilly over weight-loss drug ads, claiming misleading comparisons.CNBC · 7 hours agoNeutral Novo Nordisk CEO says GLP-1 drugs for obesity have huge growth potential and economic benefits aheadFox Business · 14 hours agoBullish Novo Nordisk stays a Buy with strong obesity drug lead and improved 2026 outlook despite near-term challenges.Seeking Alpha · 16 hours agoBullish View details →

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.